Effects of sarpogrelate on microvascular complications with type 2 diabetes

Yoo, Hyunju; Park, Inwhee; Kim, Dae Jung; Lee, Jimin

doi:10.1007/s11096-019-00794-7

Cited by 11 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported on antidiabetic drugs, such as DPP4I and SGLT2I, which reduce or delay the occurrence of diabetes complications [23][24][25][26][27][28]. Furthermore, studies have evaluated the effects of cilostazol, sarpogrelate, and antiplatelets in preventing or delaying diabetic nephropathy [29,30]. Statin has been recommended for primary and secondary prevention of cardiovascular and cerebrovascular disease with LDL-c levels below 100 mg / dL even in patients with type 2 diabetes [31].…”

Section: Discussionmentioning

confidence: 99%

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

2020

Self Cite

View full text Add to dashboard Cite

Background: The prevalence of type 2 diabetes mellitus (T2DM) is expected to increase from 7.7% in 2017 to 8.4% in 2045 worldwide. Diabetes complications contribute to morbidity and mortality. To evaluate whether the diabetes complications severity index (DCSI) was associated with increased risks of mortality and hospitalization. Methods: A retrospective cohort study was conducted using the National Health Insurance Database (NHID) sample cohort of 1,102,047 patients (2002-2015) in Korea. Diabetes complications were evaluated at 2 years after the initial diagnosis and during the subsequent follow-up period (mean duration 6.56 ± 2.81 years). The type and severity of complications were evaluated on the basis of the International Classification of Disease Ninth (ICD-9) codes used in DCSI with 7 categories and 55 subcategories of complications. The Cox proportional hazard and Poisson regression models were used to evaluate the mortality and hospitalization rates. The incidence and relative risk of diabetes complications as well as the risk of mortality and hospitalization were the main outcome measures. Results: A total of 27,871 patients were finally included and grouped by the number of complications present at 2 years. Four hundred ninety patients (5.37%) died without complications, 659 (7.31%) died with one complication and 1153 (11.85%) died with two or more complications. As DCSI at index date increased, the risk of additional new diabetes complications increased by 26% [relative risk (RR) 1.26, 95% CI 1.25-1.27]. The risks of mortality and hospitalization were linearly related to DCSI [hazard ratio 1.13 (95% CI 1.11-1.16), relative risk 1.04 (95% CI 1.03-1.06)]. Conclusions: Patients with higher incidence and severity of diabetes complications have increased risks of mortality and hospitalization.

show abstract

Section: Discussionmentioning

confidence: 99%

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

2020

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Yoo

Choo

Lee

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background The prevalence of type 2 diabetes mellitus (T2DM) is expected to increase from 7.7% in 2017 to 8.4% in 2045 worldwide. Diabetes complications contribute to morbidity and mortality. To evaluate whether the diabetes complications severity index (DCSI) was associated with increased risks of mortality and hospitalization. Methods A retrospective cohort study was conducted using the National Health Insurance Database (NHID) sample cohort of 1,102,047 patients (2002–2015) in Korea. Diabetes complications were evaluated at 2 years after the initial diagnosis and during the subsequent follow-up period (mean duration 6.56±2.81 years). The type and severity of complications were evaluated on the basis of the International Classification of Disease Ninth (ICD-9) codes used in DCSI with 7 categories and 55 subcategories of complications. The Cox proportional hazard and Poisson regression models were used to evaluate the mortality and hospitalization rates. The incidence and relative risk of diabetes complications as well as the risk of mortality and hospitalization were the main outcome measures. Results A total of 27,871 patients were finally included and grouped by the number of complications present at two years. Four hundred ninety patients (5.37%) died without complications, 659 (7.31%) died with one complication and 1,153 (11.85 %) died with two or more complications. As DCSI at index date increased, the risk of additional new diabetes complications increased by 26% [relative risk (RR) 1.26, 95% CI 1.25–1.27]. The risks of mortality and hospitalization were linearly related to DCSI [hazard ratio 1.13 (95% CI 1.11–1.16), relative risk 1.04 (95% CI 1.03–1.06)]. Conclusions Patients with higher incidence and severity of diabetes complications have increased risks of mortality and hospitalization.

show abstract

“…Studies have reported on antidiabetic drugs, such as DPP4I and SGLT2I, which reduce or delay the occurrence of diabetes complications [19][20][21][22][23][24]. Furthermore, studies have evaluated the effects of cilostazol, sarpogrelate, and antiplatelets in preventing or delaying diabetic nephropathy [25,26]. with one complication, but increased by 1.9 times in two complication, and 7.18 times in more than 5 complications.…”

Section: Discussionmentioning

confidence: 99%

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Yoo

Choo

Lee

2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background The prevalence of type 2 diabetes mellitus (T2DM) is expected to increase from 7.7% in 2017 to 8.4% in 2045 worldwide. Diabetes complications contribute to morbidity and mortality. To evaluate whether the diabetes complications severity index (DCSI) was associated with increased risks of mortality and hospitalization. Methods A retrospective cohort study was conducted using the National Health Insurance Database (NHID) sample cohort of 1,102,047 patients (2002–2015) in Korea. Diabetes complications were evaluated at 2 years after the new diagnosis of T2DM and during the follow-up period. The type and severity of complications were evaluated on the basis of the International Classification of Disease ninth (ICD-9) codes used in DCSI with 7 categories and 55 subcategories of complications. The Cox proportional hazard and Poisson regression models were used to evaluate the mortality and hospitalization rates. The incidence and relative risk of diabetes complications as well as the risk of mortality and hospitalization were the main outcome measures. Results A total of 27,871 patients were finally included and grouped into patients by the number of diabetic complications: none, one, and two or more. Out of total patients, 2,302 (8.26%) died during the follow-up period. Patients died in 490 (5.37%) of 9,130 with none, 659 (7.31%) of 9,015 with one, and 1,153 (11.85%) of 9,726 patients with two or more complications. The risks of mortality and hospitalization were related with DCSI linear [hazard ratio 1.13 (95% CI 1.11–1.16), relative risk 1.04 (95% CI 1.03–1.06)]. Conclusions The higher incidence and severity of diabetes complications have increased risks of mortality and hospitalization in patients with T2DM.

show abstract

Effects of sarpogrelate on microvascular complications with type 2 diabetes

Cited by 11 publications

References 41 publications

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Study of hospitalization and mortality in Korean diabetic patients using the diabetes complications severity index

Contact Info

Product

Resources

About